Bradley Foster & Sargent Inc. CT Sells 223,860 Shares of Abbott Laboratories $ABT

Bradley Foster & Sargent Inc. CT reduced its holdings in shares of Abbott Laboratories (NYSE:ABT) by 26.8% in the first quarter, Holdings Channel reports. The institutional investor owned 611,016 shares of the healthcare product maker’s stock after selling 223,860 shares during the period. Bradley Foster & Sargent Inc. CT’s holdings in Abbott Laboratories were worth $62,733,000 as of its most recent SEC filing.

Other large investors have also added to or reduced their stakes in the company. Lombard Odier Asset Management Switzerland SA boosted its stake in Abbott Laboratories by 19.7% during the 1st quarter. Lombard Odier Asset Management Switzerland SA now owns 107,096 shares of the healthcare product maker’s stock valued at $10,996,000 after purchasing an additional 17,600 shares during the last quarter. Lombard Odier Asset Management Europe Ltd raised its stake in shares of Abbott Laboratories by 3.1% in the first quarter. Lombard Odier Asset Management Europe Ltd now owns 18,304 shares of the healthcare product maker’s stock worth $1,879,000 after purchasing an additional 554 shares during the last quarter. Waverly Advisors LLC lifted its holdings in shares of Abbott Laboratories by 16.3% in the first quarter. Waverly Advisors LLC now owns 128,054 shares of the healthcare product maker’s stock valued at $13,147,000 after purchasing an additional 17,977 shares in the last quarter. Dempze Nancy E boosted its position in shares of Abbott Laboratories by 2.6% during the first quarter. Dempze Nancy E now owns 44,350 shares of the healthcare product maker’s stock valued at $4,553,000 after buying an additional 1,115 shares during the last quarter. Finally, Entropy Technologies LP boosted its position in shares of Abbott Laboratories by 45.9% during the first quarter. Entropy Technologies LP now owns 172,145 shares of the healthcare product maker’s stock valued at $17,674,000 after buying an additional 54,121 shares during the last quarter. Institutional investors own 75.18% of the company’s stock.

Abbott Laboratories Stock Up 2.4%

Shares of NYSE:ABT opened at $103.13 on Friday. Abbott Laboratories has a 1 year low of $81.97 and a 1 year high of $137.49. The company has a market capitalization of $179.63 billion, a PE ratio of 33.38, a price-to-earnings-growth ratio of 2.00 and a beta of 0.61. The business has a fifty day moving average price of $91.61 and a two-hundred day moving average price of $101.33. The company has a debt-to-equity ratio of 0.56, a current ratio of 1.39 and a quick ratio of 1.01.

Abbott Laboratories (NYSE:ABT) last released its earnings results on Thursday, July 16th. The healthcare product maker reported $1.31 EPS for the quarter, topping analysts’ consensus estimates of $1.28 by $0.03. The company had revenue of $12.51 billion for the quarter, compared to analysts’ expectations of $12.52 billion. Abbott Laboratories had a return on equity of 17.65% and a net margin of 11.65%.The business’s revenue for the quarter was up 13.0% compared to the same quarter last year. During the same period in the previous year, the business posted $1.26 EPS. Abbott Laboratories has set its Q3 2026 guidance at 1.380-1.46 EPS and its FY 2026 guidance at 5.450-5.60 EPS. Analysts forecast that Abbott Laboratories will post 5.52 earnings per share for the current year.

Abbott Laboratories Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Monday, August 17th. Shareholders of record on Wednesday, July 15th will be paid a $0.63 dividend. This represents a $2.52 dividend on an annualized basis and a yield of 2.4%. The ex-dividend date is Wednesday, July 15th. Abbott Laboratories’s payout ratio is presently 81.55%.

Insider Buying and Selling at Abbott Laboratories

In related news, Director Daniel J. Starks purchased 10,000 shares of the firm’s stock in a transaction dated Monday, April 27th. The stock was bought at an average price of $92.65 per share, for a total transaction of $926,500.00. Following the purchase, the director directly owned 6,751,103 shares in the company, valued at approximately $625,489,692.95. This trade represents a 0.15% increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. 0.46% of the stock is owned by corporate insiders.

Wall Street Analyst Weigh In

A number of equities research analysts recently commented on ABT shares. Citigroup increased their price target on Abbott Laboratories from $108.00 to $112.00 and gave the company a “buy” rating in a research report on Friday, July 17th. Oppenheimer reduced their target price on shares of Abbott Laboratories from $132.00 to $115.00 and set an “outperform” rating for the company in a research note on Friday, April 17th. Barclays dropped their price target on shares of Abbott Laboratories from $144.00 to $143.00 and set an “overweight” rating on the stock in a research report on Monday, April 20th. Argus cut their price target on shares of Abbott Laboratories from $140.00 to $125.00 and set a “buy” rating on the stock in a report on Tuesday, April 21st. Finally, Jefferies Financial Group reduced their price objective on shares of Abbott Laboratories from $145.00 to $135.00 and set a “buy” rating for the company in a research report on Friday, April 17th. Three investment analysts have rated the stock with a Strong Buy rating, nineteen have issued a Buy rating, three have issued a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $118.61.

About Abbott Laboratories

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.